This is to inform you that pursuant to Regulation 30 & Regulation 33 of Securities Exchange Board of India (Listing Obligation and Disclosure requirement) Regulation 2015 'Listing regulation' ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Pentokey Organy approved the audited financial results for Q4 and full year ended 31 March 2025. The company operates only in the pharma trading segment. Revenue from operations for FY25 collapsed to Rs 82.62 lakh from Rs 439.63 lakh in FY24, a sharp ~81% YoY decline. Profit before tax fell to Rs 24.55 lakh from Rs 87.25 lakh, with EPS dropping to Rs 0.39 from Rs 1.39. Total income stood at Rs 129.05 lakh versus Rs 484.77 lakh. The balance sheet remains debt-free with total equity of Rs 945.72 lakh and total assets of Rs 978.57 lakh. Operating cash flow was positive at Rs 21.66 lakh. Statutory auditor Verma Mehta & Associates issued an unmodified (clean) opinion on the financials.
This is a materially weak result with revenue nearly cut to one-fifth of last year and profits shrinking by over 70%, which is likely to be viewed negatively by shareholders. The clean audit opinion and debt-free, cash-positive balance sheet offer some comfort, but the sharp business contraction is the key concern.